Pharmaceutical equivalence and stability study of levofloxacin tablets commercialized in Europe and Africa
- Cáceres Pérez Amor R 1
- El Kory Mohamed B
- Elhadj Malick Kane
- Suárez Gonzalez Javier 1
- Betancor Inés
- Soriano Mabel
- Echezarreta Magdalena 1
- Santoveña Estevez Ana 1
- José B. Fariña Espinosa 1
-
1
Universidad de La Laguna
info
- I. Caraballo (ed. lit.)
- M.L. González-Rodríguez (ed. lit.)
- M. Casas (ed. lit.)
- A.M. Rabasco (ed. lit.)
Editorial: Sociedad Española de Farmacia Industrial y Galénica
ISBN: 978-84-09-35847-2
Año de publicación: 2021
Páginas: 53-54
Congreso: XV Congreso de la Sociedad Española de Farmacia Industrial y Galénica
Tipo: Aportación congreso
Proyectos relacionados
Referencias bibliográficas
- [1] World Health Organization. Global Tuberculosis Report 2020. 2020.
- [2] World Health Organization. A study on the public health and socioeconomic impact of substandard and falsified medical products. 2017.
- [3] Kim HJ et al. Simple and accurate quantitative analysis of 20 anti-tuberculosis drugs in human plasma using liquid chromatography–electrospray ionization–tandem mass spectrometry. J Pharm Biomed Anal. 2015;102:9-16. doi: 10.1016/j.jpba. 2014.08.026
- [4] USP. Levofloxacin tablets. 2014.
- [5] European Medicine Agency. Guideline on the investigation on the bioequivalence. 2010.